Page 302 - Haematologica April 2020

F. Baron et al.
conditioning we observed a lower risk of relapse in PBSC with ATG patients than in BMT without ATG patients (HR=0.56, 95% CI: 0.39-0.81, P=0.002) while this was not the case in patients given chemotherapy-based condition- ing (HR=0.94, 95% CI: 0.70-1.26, P=0.68).
The 2-year CI of non-relapse mortality was 18% in BMT without ATG patients versus 16% in PBSC with ATG patients (P=0.16) (Figure 2D). On multivariate analysis, there was a non-significant trend for lower NRM in PBSC with ATG patients (HR=0.7, 95% CI: 0.7-
Table 3. Patient characteristics among 10/10 human leucocyte antigen-matched unrelated donor recipients.
Variable
Follow up, median (95% CI)
Age of patient at HSCT (years), Median (IQR)
Sex, n (%) Male Female Missing
Karnofsky, n (%) <80
≥80
Missing
Status at transplant, n (%) CR1
CR2
Cytogenetic risk Good1
Intermediate2 Poor3
Missing
AML type Primary Secondary
Year of transplant, Median (IQR)
Sex mismatch, n (%) Female to male
CMV donor/patient, n (%)
-/- +/- -/+ +/+
Missing
Conditioning, n (%) Chemotherapy -based MAC4
TBI-based MAC
Post-grafting immunosuppression, n (%)
CNI + MTX CNI + MMF CNI alone Other/missing
ATG, n (%)
Thymoglobuline
Median (IQR) dose, mg/kg
ATG-Fresenius
Median (IQR) dose, mg/kg
Missing
BM without ATG (n=303)
5.0 (4.0-5.4)
42 (31-50)
152 (50) 151 (50) 0
6 (2) 283 (98) 14
215 (71) 88 (29)
30 (14) 137 (65) 43 (21) 93
277 (91) 26 (9)
2012 (2009-2014) 28 (9)
99 (34) 27 (9) 84 (28) 85 (29) 8
189 (62) 114 (38)
262 (86) 17 (6) 8 (3) 16 (5)
−
−
−
PBSC with ATG P (n=2318)
2.7 (2.5-3.0)
48 (37-56)
1210 (52) 1108 (48) 0
46 (2) 2156 (98) 116
<0.001 0.50
0,99
1836 (79) 0.001 482 (21)
0.94
0.014
2013 (2011-2015)
279 (12) 0.15
176 (14) 793 (64) 266 (22) 1083
2002 (86) 316 (14)
<0.001
608 (27) 179 (8) 703 (32) 741 (33) 87
1873 (81) 445 (19)
1468 (63) 556 (24) 134 (6) 160 (7)
736 (42) 5.5 (5.0-6.0)
1013 (58)
40 (30-60)
569
0.09
<0.001
HLA: human leucocyte antigen; MUD: 10/10 HLA-matched unrelated donors; CI: confidence interval; BM: bone marrow; PBSC: peripheral blood stem cells; AML: acute myeloid leukemia; ATG: anti-thymocyte globulin; HSCT: hematopoietic stem cell transplantation; IQR: interquartile range; CR: complete remission; CMV: cytomegalovirus; MAC: myeloab- lative conditioning; TBI: total body irradiation; CNI: calcineurin inhibitor; MTX: methotrexate; MMF: mycophenolate mofetil;1defined as t(8;21), t(15;17), inv or del (16), or acute promyelocyticleukemia, these abnormalities only or combined with others; 2defined as all cytogenetics not belonging to the good or high risk (including trisomies); 3defined as 11q23 abnormalities, complex karyotype, abnormalities of chromosomes 5 and 7, as well as 3q26 and 17p abnormalities, as defined previously16; 4defined as use of ≥ 6 Gy TBI, busulfan > 8 mg/kg, or melphalan > 140 mg/m2.
1144
haematologica | 2020; 105(4)